Link to this page
The Drug-Drug Interactions Ontology
Last uploaded:
February 11, 2016
| Id | http://purl.obolibrary.org/obo/dinto_DB05266
http://purl.obolibrary.org/obo/dinto_DB05266
|
|---|---|
| Preferred Name | ibudilast |
| Synonyms |
C14H18N2O
2-methyl-1-[2-(propan-2-yl)pyrazolo[1,5-a]pyridin-3-yl]propan-1-one
|
| Type | http://www.w3.org/2002/07/owl#Class |
All Properties
| prefLabel | ibudilast
|
|---|---|
| label | ibudilast
|
| DBSynonym |
ibudilast [inn:jan]
ibudilastum [latin]
3-isobutyryl-2-isopropylpyrazolo(1,5-a)pyridine
ke tas
ibudilastum
mn-166
i0157_sigma
3-isobutyryl-2-isopropylpyrazolo[1,5-a]pyridine
av-411
2-isopropyl-3-isobutyrylpyrazolo(1,5-a)pyridine
eyevinal
lopac-i-0157
unii-m0tth61xc5
tocris-1694
ibudilast (jan/inn)
pyrazolo(1,5-a)pyridine, 3-isobutyryl-2-isopropyl-
ketas
ketas (tn)
See more
See less
|
| ATCCode | R03DC04
|
| Definition | Ibudilast is an anti-inflammatory and neuroprotective oral agent which shows an excellent safety profile at 60 mg/day and provides significantly prolonged time-to-first relapse and attenuated brain volume shrinkage in patients with relapsing-remitting (RR) and/or secondary progressive (SP) multiple sclerosis (MS). Ibudilast is currently in development in the U.S. (codes: AV-411 or MN-166), but is approved for use as an antiinflammatory in Japan.
|
| has pharmacological target | |
| inhibits | |
| type | |
| InChIKey | InChIKey=ZJVFLBOZORBYFE-UHFFFAOYSA-N
|
| Synonym |
C14H18N2O
2-methyl-1-[2-(propan-2-yl)pyrazolo[1,5-a]pyridin-3-yl]propan-1-one
|
| xref |
PharmGKB:PA165958351
PubChem Substance:99443231
BindingDB:50240404
ChemSpider:3543
Wikipedia:http://en.wikipedia.org/wiki/Ibudilast
PubChem Compound:3671
See more
See less
|
| CASRN | 50847-11-5
|
| prefixIRI | obo2:dinto_DB05266
|
| SMILES | CC(C)C(=O)C1=C2C=CC=CN2N=C1C(C)C
|
| InChI | InChI=1S/C14H18N2O/c1-9(2)13-12(14(17)10(3)4)11-7-5-6-8-16(11)15-13/h5-10H,1-4H3
|
| subClassOf |
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |